To analyze the incidence,clinical manifestations and causes of 42 in patients with anaphylaxis from 1990 and follow its change before and after 2005 retrospectively.The mean age was (39 ± 16) years.The ratio of male and female was 1:2.2.The incidence increased obviously after 2005 (30 vs.12).A majority of patients were females after 2005 (24 vs.5).The proportions of patients with impaired nerve system,circulatory system and hypotension decreased after 2005 (P ＜ 0.01,P ＜ 0.05,P ＜ 0.01).Anaphylaxis attacked more often intra-operatively after 2005 (43.3 ％ vs.1 / 12).The most common cause was drug(35/42),especially antibiotics(14/35).

Mast cells are the main effector cells in allergic diseases. Allergic diseases are mostly a direct result of mast cell mediator release effects, while allergen activation is only one of many triggers for mast cell mediator secretion. Increased mast cell number, high mast cell reactivity, or both can lead to abnormal mast cell activation. Mast cell activated syndrome (MCAS) refers to a group or a"spectrum"of mediator-related, symptomatically similar diseases in which mast cells are stimulated by multiple factors. The symptoms and signs of mast cell disease overlap with allergic diseases, but the etiology is different, which requires clinical attention. This article summarizes the research progress on mast cell activation syndrome in recent years thus increase awareness of the differential diagnosis.

The prevalence of allergic diseases has gradually increased worldwide along with the development of industrialization, changes in environmental factors, adjustment of people′s diet structure and increasing exposure to allergens. Allergic diseases have become an important challenge to global public health strategies. Meanwhile, the coexistence with allergic rhinitis, and(or) allergic asthma, and(or) atopic dermatitis and other allergic diseases in a single patient is becoming more and more prevalent. Allergic comorbidities and multimorbidities will inevitably increase the difficulty of treating and recovery, seriously affect patients′ quality of life, and greatly increase the burden on social medical insurance. Understanding the underlying mechanisms of comorbidities and multimorbidities has both preventive and therapeutic significance. This article reviews the research progress of allergy comorbidity and multimorbidity in order to address the importance of this phenominon, stimulate clinical attention and provide a reference for the formulation of prevention and treatment strategies.

Objective　To observe in vitro effects and morphological changes of human peripheral blood dendritic cells (DCs) on the ability of lymphokine and phytohaemagglutininum (PHA) activated killer (LPAK) cells to induce apoptosis of the human hepatoma cell line (BEL-7402， B). Methods　Experimental groups were divided into LD group （DCs+L+B）, L group （L+B）， D group （DCs+B） and B group. The methods of neutral red uptake, ordinary light microscopy, electron microscopy, TDT mediated X-dUTP nick end labeling (TUNEL) were used. Results　The difference between the D group and the B group was not distinct (P>0.05). The difference between the LD group and the L group was distinct， with DCs+LPAK >LPAK (P<0.01) in cytotoxity. Apoptotic cells were TUNEL positive in light microscopy, and apoptotic nuclei were stained yellow brown and dark brown, with size and shape varying from cell to cell. Ultrastructural change in apoptotic tumor cells comprised of compaction and condensation of nuclear chromatin， and condensation of cytoplasm and apoptotic bodies. At the same time, LPAK cells manifested the characteristics of autophagic apoptosis, and there were some autophagic bodies in it. Conclusions　The combination of human blood DCs and LPAK cells could induce apoptosis of BEL-7402 cells effectively, with some LPAK cells manifesting the characteristics of autophagic apoptosis.

Mast cells are the main effector cells in allergic diseases. Allergic diseases are mostly a direct result of mast cell mediator release effects, while allergen activation is only one of many triggers for mast cell mediator secretion. Increased mast cell number, high mast cell reactivity, or both can lead to abnormal mast cell activation. Mast cell activated syndrome (MCAS) refers to a group or a"spectrum"of mediator-related, symptomatically similar diseases in which mast cells are stimulated by multiple factors. The symptoms and signs of mast cell disease overlap with allergic diseases, but the etiology is different, which requires clinical attention. This article summarizes the research progress on mast cell activation syndrome in recent years thus increase awareness of the differential diagnosis.

The prevalence of allergic diseases has gradually increased worldwide along with the development of industrialization, changes in environmental factors, adjustment of people′s diet structure and increasing exposure to allergens. Allergic diseases have become an important challenge to global public health strategies. Meanwhile, the coexistence with allergic rhinitis, and(or) allergic asthma, and(or) atopic dermatitis and other allergic diseases in a single patient is becoming more and more prevalent. Allergic comorbidities and multimorbidities will inevitably increase the difficulty of treating and recovery, seriously affect patients′ quality of life, and greatly increase the burden on social medical insurance. Understanding the underlying mechanisms of comorbidities and multimorbidities has both preventive and therapeutic significance. This article reviews the research progress of allergy comorbidity and multimorbidity in order to address the importance of this phenominon, stimulate clinical attention and provide a reference for the formulation of prevention and treatment strategies.

Objective To develop an expert consensus on subcutaneous injection for allergen-specific immunotherapy.Methods Relevant domestic and intemational literature was reviewed,and nursing experts who had experiences in subcutaneous injection of allergen-specific immunotherapy were interviewed to form the initial draft of the consensus.A total of 85 experts from 42 hospitals nationwide were invited to participate in discussions.2 rounds of expert consultations,adjustments,revisions,and improvements were made to the initial draft,and an online meeting was held to form the final version of the consensus.The content approved by more than 75％of the expert group is adopted,or it will be discussed or deleted.Results The expert consensus includes operational standards for subcutaneous injection of allergen-specific immunotherapy,identification and management of adverse reactions,and health education.Conclusion The consensus demonstrates strong scientific rigor and practicality,providing guidance for nursing practices in the field of clinical allergology.